Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Duke University
University of Kentucky
Northwestern University
Fred Hutchinson Cancer Center